Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Why Is Aclaris Therapeutics (ACRS) Stock Down -9.95% Today?

Why Is Aclaris Therapeutics (ACRS) Stock Down -9.95% Today?

Key Takeaways

  • Aclaris Therapeutics (ACRS) fell 9.95% to $3.53 in early trading, down from Friday's close of $3.92.
  • The primary catalyst was a Phase 2 failure: top-line ADMIRATION data showed bosakitug (ATI-045) missed its primary EASI endpoint and all secondary endpoints in moderate-to-severe atopic dermatitis.
  • Shares opened 15.6% lower at $3.31 and recovered roughly half the gap, after falling as much as 21% in pre-market trading.
  • Secondary driver: management paired the miss with a same-day Phase 2b launch of modzatinib in lichen planus and reaffirmed 2027 milestones, which limited the damage.
  • The broader tape was risk-off, with biotech and small caps underperforming the S&P 500.
  • News Significance Score: 46/100 — A major clinical miss, though the drop was only about 2.8 times the stock's typical daily swing.
  • Traders are now watching analyst target revisions, the ATI-052 eosinophilic esophagitis program, and fourth-quarter results expected in late February.
  • For deeper research, explore Price Targets, Earnings, and Forecast pages covering ACRS.
  • Readers can also review the curated Trending AI Robots section for AI-driven strategies on active tickers.

Opening Summary

Aclaris Therapeutics (ACRS) is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, developing small-molecule and biologic candidates for immuno-inflammatory diseases, alongside a contract research business. In early trading Monday, the stock fell 9.95% to $3.53, down from the prior session's close of $3.92, confirming a decisive move lower. The decline was triggered by top-line Phase 2 results showing that bosakitug, the company's anti-TSLP monoclonal antibody, failed to beat placebo on the primary and secondary endpoints of the ADMIRATION trial in atopic dermatitis. The reaction was severe at the open but moderated as buyers stepped in.

Clinical Setback: Bosakitug Misses in Atopic Dermatitis

The ADMIRATION trial did not achieve its primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at week 24, and also missed secondary endpoints. The company reported that pharmacodynamic data showed robust TSLP target engagement and downregulation of Th1, Th2 and Th17 immune-activation biomarkers, and that bosakitug was generally well tolerated. Those findings were not enough to offset the efficacy failure.

Chief Executive Dr. Neal Walker said the company was disappointed the trial "did not overcome the historical challenges of addressing atopic dermatitis with an anti-TSLP monoclonal antibody alone." For a company with roughly $560 million in market value and no approved products, removing a late-stage biologic from the near-term value equation matters, and the initial 21% pre-market decline reflected that.

Pipeline Reprioritization Cushions the Blow

The sell-off was contained by the rest of the release. Aclaris said development priorities are unchanged and remain centered on its oral kinase inhibitors and ATI-052, an anti-TSLP/IL-4Rα bispecific antibody. On the same morning, the company announced initiation of the Phase 2b ALPHA trial of modzatinib (ATI-2138) in lichen planus, an indication with no approved therapies, where the drug holds FDA Fast Track designation. Oral erosive lichen planus cohort data are expected in the second half of 2027.

Management also reiterated plans to file an IND for ATI-9494 this quarter, with a Phase 1 program starting in the first quarter of 2027, and to begin a Phase 2b trial of ATI-052 in eosinophilic esophagitis in the same period. The company held $204.6 million in cash and marketable securities at September 30. That framing shifted the narrative from a single-asset failure to a diversified, multi-asset story — consistent with the intraday rebound from $3.31 toward $3.50.

Positioning Unwind After a Pre-Readout Rally

Part of the move reflects the undoing of event-driven positioning. ACRS had climbed roughly 28% from $3.38 in mid-October to $4.34 on November 11 as traders built exposure into a binary readout, with a Strong Buy consensus and price targets clustered in the $8 to $13 range. When the data disappointed, that de-risking flow amplified the gap lower. The stock has now given back all of that advance and trades about 20% below its 50-day average near $4.43.

Market Context and Trading Activity

Volume was clearly elevated: more than 1 million shares changed hands in the first 25 minutes, a pace roughly four times the stock's typical full-day turnover of about 1.65 million shares. The move was company-specific rather than sector-driven. The SPDR S&P Biotech ETF (XBI) slipped about 1.2%, the iShares Biotechnology ETF (IBB) fell 0.6%, the Russell 2000 proxy (IWM) lost 0.8% and the S&P 500 proxy (SPY) was down 0.8%, so the broader tape added modest pressure but explains only a fraction of the decline. Technically, the gap opened below recent consolidation support in the $3.70–$4.00 zone and well under the 50-day average, leaving the 52-week low of $2.34 as the next reference point.

News Significance Score

The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Aclaris scores 46 out of 100.

The verified news was substantial: a lead biologic missed both primary and secondary endpoints in a mid-stage atopic dermatitis trial, a material event for a company of this size, though softened by an unchanged pipeline and a well-funded balance sheet. The price move itself was notable but not extreme — roughly 2.8 times the stock's 3.5% average absolute daily change, with only three larger single-session moves in the past 60 sessions. Elevated volume supports the high end of that band. A major catalyst combined with a moderately unusual move lands the score in the mid-40s.

What Comes Next for ACRS

Fourth-quarter and full-year 2026 results are expected in late February, and attention will focus on spending, cash runway and any impairment tied to bosakitug. Near-term catalysts include the ATI-9494 IND filing this quarter, the start of the ATI-052 Phase 2b trial in eosinophilic esophagitis in the first quarter of 2027, and modzatinib oral lichen planus data in the second half of 2027. Analyst revisions are likely, and consensus targets above $10 will need to be reassessed against the reduced contribution from bosakitug in skin disease. Risks include further pipeline setbacks, financing needs and continued risk aversion toward unprofitable small-cap biotech.

Trending AI Robots

Tickeron's Trending AI Robots page collects the strongest-performing automated strategies under current market conditions from a library of hundreds of AI trading bots spanning thousands of tickers. Bots differ by strategy, timeframe, performance metrics and traded symbols, so results vary widely across market environments. The curated list highlights only those currently standing out. Reviewing it can help traders see which approaches are working right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ACRS

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Aroon Indicator for ACRS shows an upward move is likely

ACRS's Aroon Indicator triggered a bullish signal on November 17, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 232 similar instances where the Aroon Indicator showed a similar pattern. In 197 of the 232 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACRS's RSI Indicator exited the oversold zone, 21 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for ACRS just turned positive on October 21, 2026. Looking at past instances where ACRS's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.

Following a +17.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRS advanced for three days, in 222 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACRS as a result. In 71 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

The 50-day moving average for ACRS moved below the 200-day moving average on November 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

ACRS broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.608) is normal, around the industry mean (3.592). P/E Ratio (-6.724) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (83.333) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. ACRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interesting Articles
A.I. Advisor
published General Information

General Information

a manufacturer of novel dermatological therapies

Industry Biotechnology

Industry
Pharmaceuticals Other
Address
701 Lee Road
Phone
+1 484 324-7933
Employees
73
Web
https://www.aclaristx.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.